Arcutis insider plans Rule 144 stock sale

Arcutis Biotherapeutics insider Todd Edwards filed a notice to sell 2,052 shares of common stock under Rule 144.

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider Todd Edwards filed a notice to sell 2,052 shares of common stock under Rule 144. The planned sale, through Merrill on NASDAQ, has an aggregate market value of $52,322.72 and an approximate sale date of February 2, 2026.

The shares to be sold were acquired as restricted stock that vested on February 1, 2026 from Arcutis Biotherapeutics Inc. The filing also reports that Edwards sold 29,131 common shares on November 6, 2025 for gross proceeds of $732,051.95 during the prior three months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Arcutis Biotherapeutics (ARQT) Form 144 filing disclose?

The filing discloses that insider Todd Edwards plans to sell 2,052 shares of Arcutis Biotherapeutics common stock under Rule 144. The planned sale has an aggregate market value of $52,322.72 and is expected to be executed on NASDAQ through Merrill.

How many Arcutis Biotherapeutics (ARQT) shares is Todd Edwards planning to sell?

Todd Edwards plans to sell 2,052 shares of Arcutis Biotherapeutics common stock. The filing lists an aggregate market value of $52,322.72 for this block, with Merrill as broker and an approximate sale date of February 2, 2026 on NASDAQ.

How did Todd Edwards acquire the Arcutis Biotherapeutics (ARQT) shares being sold?

The shares were acquired as restricted stock that vested on February 1, 2026 from Arcutis Biotherapeutics Inc. The Form 144 indicates a “restricted shares vest” transaction type, with 2,052 securities acquired on that date and scheduled for potential resale.

What prior Arcutis Biotherapeutics (ARQT) share sales by Todd Edwards are reported?

The notice reports that Todd Edwards sold 29,131 shares of Arcutis Biotherapeutics common stock on November 6, 2025. Those sales generated gross proceeds of $732,051.95 and are disclosed as securities sold during the past three months.

Which broker and exchange are listed for the planned Arcutis Biotherapeutics (ARQT) sale?

The planned Rule 144 sale lists Merrill as the broker, with an address on Lyra Drive in Columbus, Ohio. The securities are identified for trading on NASDAQ, with an approximate sale date of February 2, 2026 for the 2,052-share transaction.

What type of Arcutis Biotherapeutics (ARQT) security is covered in this Form 144?

The Form 144 covers sales of Arcutis Biotherapeutics common stock. It specifies the class as “Common,” with 2,052 shares planned for sale and 122,492,192 shares outstanding cited as context in the securities information table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 06:17 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001994805
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Todd Edwards
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Flr Columbus OH 43215	2052	52322.72	122492192	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/01/2026	Restricted shares vest	Arcutis Biotherapeutics Inc			2052	02/01/2026	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Todd Edwards 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	11/06/2025	29131	732051.95

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Todd Edwards
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)